Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellsperformance statuswomenimmunotherapytherapy
  Phrases that lowered it: to investigateand safetyefficacy andsafety ofdonation
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 31.8% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 95.6% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 45894 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 5 (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients NCT01588769 · started 2011 · scored riskier than 50% of active trials completed
• Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma NCT02799238 · started 2016 · scored riskier than 96% of active trials completed
• Dendritic Cell Cancer Vaccine for High-grade Glioma NCT01213407 · started 2010 · scored riskier than 80% of active trials completed
• A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) NCT01280552 · started 2011 · scored riskier than 94% of active trials completed
• A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma NCT02820584 · started 2016 · scored riskier than 34% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.